Hemostasis Today

April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Francisco Chacón-Lozsán: Bleeding on Anticoagulation Is Not a Complication, It’s a Turning Point
Apr 8, 2026, 14:13

Francisco Chacón-Lozsán: Bleeding on Anticoagulation Is Not a Complication, It’s a Turning Point

Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared on LinkedIn about a recent article by Mattia Galli et al, published in European Heart Journal:

”Bleeding on anticoagulation is NOT a complication… it’s a turning point

The problem

We prescribe anticoagulants to prevent:

  • Stroke
  • MI
  • VTE

But the most frequent complication is: Bleeding

And here’s the uncomfortable truth: Bleeding often determines prognosis more than thrombosis

Why this matters

Bleeding is NOT just an event.

It triggers:

  • Treatment interruption
  • Fear-driven underdosing
  • Permanent discontinuation

Leading to higher prevalence of stroke,  MI and mortality

Key clinical reality

Major bleeding:

  • approximately 1-3% per year
  • 30-day mortality >15%
  • 1-year mortality >25%

That’s NOT benign

The real battlefield

Every anticoagulated patient lives here: Thrombosis vs Bleeding

And we often focus on only one side.

 What experts are telling us (ESC)

This is the new paradigm

1. Risk is dynamic

Bleeding risk is highest:

  • Early after starting anticoagulation
  • In elderly / multimorbid patients

Reassess continuously, not once

2.Not all bleeding is equal

Critical sites equal high mortality:

  • Intracranial
  • GI
  • Retroperitoneal
  • Pericardial

Even small volumes can kill

3.Combination therapy is dangerous

OAC plus antiplatelet equals 2–3 times higher risk for bleeding

  • De-escalate EARLY
  • Avoid triple therapy when possible

4.Prevention is powerful

Simple interventions:

  • PPI for GI protection
  • Avoid NSAIDs / SSRIs when possible
  • Correct dosing (DOAC underdosing equals worse outcomes)

Most bleeding is preventable.

When bleeding happens

Think in 3 steps:

 1. Stabilize

  • Stop anticoagulant
  • Airway, oxygen, access
  • Fluids plus transfusion

2. Reverse (if needed)

  • VKA: PCC plus Vitamin K
  • Dabigatran: Idarucizumab
  • FXa inhibitors: PCC (± Andexanet)

3. Find and control the source

  • Endoscopy
  • IR embolization
  • Surgery

The biggest mistake:  ‘Let’s stop anticoagulation and never restart’

The evidence says:

NOT restarting = higher risk for stroke plus death

  • Restart early when safe
  • Individualize timing plus dose

The future

We are moving toward:

  • Personalized anticoagulation
  • Dose tailoring
  • Drug selection based on bleeding profile

Take-home message

Anticoagulation is NOT binary.

It is:

  • A continuous balance
  • A dynamic decision
  • A personalized therapy

Final thought: The goal is not to avoid bleeding. The goal is to survive both bleeding AND thrombosis.

Reference: Galli, M., Simeone, B., ten Berg, J., et al. (2026). European Heart Journal: Acute Cardiovascular Care.”

Title: Managing bleeds on anticoagulant therapy: a practical guide for clinicians

Authors: Mattia Galli , Beatrice Simeone , Jurrien ten Berg , Davide Capodanno , Marco Valgimigli , Sebastiano Sciarretta , Ernesto Greco , Adnan Kastrati , Gilles Montalescot , C Michael Gibson , Diana A Gorog , Roxana Mehran , Dominick J Angiolillo

Read the Full Article on European Heart Journal

Francisco Chacón-Lozsán: Bleeding on Anticoagulation Is Not a Complication, It’s a Turning Point

Stay updated on all scientific advances with Hemostasis Today.